Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity.
about
Improving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cellsPriming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cellsRecombinant Mycobacterium bovis BCG as an HIV vaccine vector.Vaxvec: The first web-based recombinant vaccine vector database and its data analysisDetection of natural infection with Mycobacterium intracellulare in healthy wild-caught Chacma baboons (Papio ursinus) by ESAT-6 and CFP-10 IFN-gamma ELISPOT tests following a tuberculosis outbreakDual neonate vaccine platform against HIV-1 and M. tuberculosis.A novel high-throughput vaccinia virus neutralization assay and preexisting immunity in populations from different geographic regions in ChinaPre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG.Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection.Priming with recombinant auxotrophic BCG expressing HIV-1 Gag, RT and Gp120 and boosting with recombinant MVA induces a robust T cell response in mice.Newborn mice vaccination with BCG.HIVA²²² + MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routesEngineering new mycobacterial vaccine design for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCGMycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease ControlVaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding.B5-deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals.Lactoferrin enhanced efficacy of the BCG vaccine to generate host protective responses against challenge with virulent Mycobacterium tuberculosisProgress towards an HIV vaccine based on recombinant bacillus Calmette-Guérin: failures and challenges.Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses.Smallpox vaccines for biodefense.Balancing Trained Immunity with Persistent Immune Activation and the Risk of Simian Immunodeficiency Virus Infection in Infant Macaques Vaccinated with Attenuated Mycobacterium tuberculosis or Mycobacterium bovis BCG Vaccine.Justification for the inclusion of Gag in HIV vaccine candidates.Recombinant Mycobacterium bovis bacillus Calmette-Guérin vectors prime for strong cellular responses to simian immunodeficiency virus gag in rhesus macaques.Recombinant vaccinia DIs expressing simian immunodeficiency virus gag and pol in mammalian cells induces efficient cellular immunity as a safe immunodeficiency virus vaccine candidate.
P2860
Q28543248-B279EFB6-F627-40C4-91DC-40E3E12A2425Q28730854-BE2C9E89-1C2C-4463-AC6C-43CABF1D00A9Q30387447-D95CEC7F-A894-4FC3-9900-A428841FD521Q30996881-57A05ADA-5B30-4F27-A1E3-1C1706352DC3Q33318591-A0F94FA5-ED52-41C4-B8CB-6409834563BDQ33908584-FD0EFE60-AF84-4D55-9E2B-E5A610F77721Q34206208-F517B53A-61DC-432C-B381-F59387EE8757Q34395523-59F7A90A-BB95-4C4F-BC3E-8CF97D85A02DQ34648429-76D60F4D-5A9E-45DF-8C0D-1A534CEC9DAAQ34971570-29D20366-10D5-49BF-A9AF-C8EEDB13EF97Q34983688-C0FD286E-10B2-41B3-A625-2E9376587266Q35184235-18951E66-B3F7-4C57-AA92-80066E9A4E95Q35909944-832100D6-C3DD-448F-B0B5-A9C72C179A43Q35947967-28D3E4DD-092B-4293-9850-A04E0BCA8F3CQ36103012-61E33C8E-AE14-4B93-88AE-B3853F7D3BCCQ36143523-F71DE925-EB84-457F-A57B-9995F7F02544Q36690291-F1E8B2AB-6C80-47AF-8D4B-51536243906BQ36759963-A4811E89-8CD2-448A-AC19-3ADA9D3BA47CQ37191912-58A88EC8-B5E8-40FD-8020-1352144EDDCEQ37393765-919B4631-2B65-42D9-971F-3D51AE10D4FAQ37563616-B0FA0AB3-4FD4-45A4-8E85-E4F9A9064A52Q38662319-4B8076A4-E301-402C-A52B-D08CB11C800BQ42015551-9835A94E-D825-4823-9750-A019DCCB7B11Q45408958-BE1CD6E9-9B16-489B-848D-12D38605C6FA
P2860
Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Priming-boosting vaccination w ...... asting and effective immunity.
@ast
Priming-boosting vaccination w ...... asting and effective immunity.
@en
Priming-boosting vaccination w ...... asting and effective immunity.
@nl
type
label
Priming-boosting vaccination w ...... asting and effective immunity.
@ast
Priming-boosting vaccination w ...... asting and effective immunity.
@en
Priming-boosting vaccination w ...... asting and effective immunity.
@nl
prefLabel
Priming-boosting vaccination w ...... asting and effective immunity.
@ast
Priming-boosting vaccination w ...... asting and effective immunity.
@en
Priming-boosting vaccination w ...... asting and effective immunity.
@nl
P2093
P2860
P1433
P1476
Priming-boosting vaccination w ...... asting and effective immunity.
@en
P2093
Katsuaki Shinohara
Kazuhiro Matsuo
Kenji Someya
Koji Sakai
Masaru Kanekiyo
Mitsuo Honda
Naoto Yoshino
Shigeo Horibata
Shudo Yamazaki
Sohkichi Matsumoto
P2860
P304
12871-12879
P356
10.1128/JVI.79.20.12871-12879.2005
P407
P577
2005-10-01T00:00:00Z